A Case of Fatal Familial Insomnia Initially Developing Parkinsonism Mimicking Dementia with Lewy Bodies

Takuya Fukuoka, Yoshihiko Nakazato, Masaomi Yamamoto, Akifumi Miyake, Takashi Mitsufuji and Toshimasa Yamamoto

Abstract:
We report a rare case of fatal familial insomnia in a 58-year-old man who initially developed parkinsonism, secondary dementia, and visual hallucinations that were suspected to be due to dementia with Lewy bodies. We evaluated the function of the striatum via dopamine transporter SPECT using $^{123}$I-ioflupane and found marked presynaptic dopamine dysfunction in the bilateral striatum. This is the first reported case in which the initial symptom of fatal familial insomnia was parkinsonism and in which the dopamine transporter function was evaluated by DAT SPECT.

Key words: fatal familial insomnia, parkinsonism, DAT SPECT


Introduction
Fatal familial insomnia (FFI) is a rare, neurodegenerative and autosomal dominant prion disease. The initial manifestation in patients with this disease is usually insomnia (1). It is linked to an aspartic acid to asparagine substitution (D178 N) mutation at codon 178 of the prion protein gene ($PRNP$), in conjunction with methionine at the polymorphic position 129 of the mutant allele (2, 3). As the disease progresses, motor disturbances such as myoclonus, ataxia, and spasticity occur, as well as dysarthria and dysphagia (3-6). In addition, parkinsonism can be a symptom of FFI. We herein report a rare case of FFI that initially manifested as parkinsonism mimicking dementia with Lewy bodies (DLB). We evaluated the function of the dopamine nerve terminals in the striatum using dopamine transporter single-photon emission computed tomography (DAT SPECT) using $^{123}$I-ioflupane. The function of the dopamine nerve terminals in patients with FFI has not previously been described.

Case Report
A 58-year-old man presented to our hospital with a 4-month history of a weak voice, a 3-month history of significant (20 kg) weight loss, short-stepped gait, and repetitive mistakes at work; and a 2-month history of visual hallucinations (worms or worm-like visions and masked face). His familial medical history revealed that his mother may have died from Creutzfeldt-Jakob disease at 60 years of age; however, her detailed medical history was unavailable. The patient initially had no dysautonomia that might have induced hyperhidrosis, hyperthermia, tachycardia, or hypertension, and no insomnia. On admission, his body temperature was 36.4°C, his blood pressure was 150/77 mmHg, and his pulse rate was 72 bpm. A neurologic examination revealed dementia (Mini-Mental State Examination score: 13), visual hallucinations and parkinsonism (tremor, rigidity, bradykinesia, short-stepped gait and postural instability). The other neurological findings were normal. Serologic tests were negative, and his paraneoplastic and thyroid antibody levels were normal. A routine cerebrospinal fluid analysis revealed normal results and cerebrospinal fluid was negative 14-3-3 protein. Brain T1-weighted magnetic resonance imaging (MRI) disclosed slight diffuse cortical atrophy; diffusion MRI revealed no abnormal findings. Technetium-99 m ethyl cysteinate dimer SPECT indicated a decline in the blood perfusion of the cerebral cortex and bilateral thalamus. Polysomnography indicated a reduction in total sleep time, lack of REM sleep, and increased arousal. EEG showed diffuse...
slow waves without periodic spike discharges. We performed two further SPECT examinations using 123I-ioflupane as a marker for dopamine transporter binding at 4 months and 5 months after the onset of symptoms. The specific binding ratios (SBRs) of the right and left sides were 3.98 and 3.82, respectively, at 4 months; and 1.93 and 2.14 (right and left, respectively) at 5 months (Figure). The threshold for normal function in our institution was 4.5; thus, the presynaptic striatal dopaminergic nerve terminals showed a decreased function, which declined rapidly over the month between tests.

We initially suspected that the patient might have DLB based on the parkinsonism and visual hallucinations, despite the fact that his clinical symptoms progressed more rapidly in comparison to typical DLB. We prescribed levodopa (peak dose: 1,200 mg/day) during the 2 months for which he was inpatient; however this was ineffective and his clinical symptoms progressed much more rapidly than the symptoms of a patient with DLB would have. His dementia progressed to the extent that he could not complete the MMSE. Sympathetic autonomic symptoms (hypertension, sweating, remittent fever) and insomnia manifested and progressed during this time. At seven months, the patient demonstrated laryngeal stridor, swallowing dysfunction, and aspiration pneumonia. He required mechanical ventilation, followed by tracheostomy and died due to pneumonia 9 months later. Based on the clinical course, we sequenced DNA extracted from the peripheral blood leukocytes, and identified a D178N mutation with methionine/methionine homozygosity at the polymorphic codon 129 of PRNP. Based on this result we formally diagnosed the patient with FFI.

**Discussion**

Our patient was confirmed as having probable FFI, despite initially presenting with parkinsonism, secondary dementia and visual hallucinations that were suspected to have been caused by DLB and was finally diagnosed with FFI based on gene sequencing of DNA. Although three previous reports (5-7) have described FFI patients with parkinsonism (Table), there are no previous reports of cases in which parkinsonism was the initial symptom of FFI.

DAT SPECT imaging assesses the functional status of the nigrostriatal dopaminergic system, and can provide a marker of presynaptic neuronal degeneration. A reduced striatal uptake (i.e. lower DAT SBR) is associated with extrapyramidal
signs, such as bradykinesia and rigidity (8); in this patient the DAT SBRs were initially below the threshold for dysfunction at our institution, and rapidly worsened. DAT SPECT revealed the dysfunction of the presynaptic dopamine neurons in the striatum. Levodopa had no effect on the patient’s parkinsonism. These findings demonstrate damage of both presynaptic and postsynaptic dopaminergic systems. Klöppel et al. reported two cases of FFI without parkinsonism that were examined by 2-β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT) SPECT. They reported that β-CIT SPECT showed a region-specific uptake with the highest activity in the striatum, which corresponded to striatal dopamine transporters, suggesting a normal presynaptic dopamine system (9). However, DAT SPECT imaging of the presynaptic dopamine neurons with the ligand (123)I-2beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane ((123)I-FP-CIT), which binds to the DAT reuptake site and visualizes the presynaptic function related to the parkinsonism. DAT SPECT could directly evaluate the presynaptic neuronal degeneration and the reduced striatal uptake, and thus provided high sensitivity in the detection of parkinsonism in FFI. Atrophy of the anterior ventral and mediodorsal nuclei of the thalamus, which can be observed by a histopathological examination, remains the most prominent change in FFI; however, various degrees of atrophy and reactive astrogliosis have been found in other thalamic nuclei, the cerebral and cerebellar cortexes, and the olives (3). Moreover, apoptotic neurons were also found in the neocortex and striatum of FFI patients who are heterozygous (methionine/valine) for the polymorphism at codon 129 (M129V) of PRNP, who demonstrate a longer disease duration and more widespread cerebral changes. In contrast, in patients who are homozygous for the polymorphism at codon 129 (M129M) of PRNP, the involvement of the cerebral cortex and striatum was reported to generally be inconspicuous and restricted to inconstant rare spongiform change (10). We could find marked presynaptic dopamine dysfunction in the bilateral striatum using DAT SPECT, even if the striatum change was generally pathologically inconspicuous in this case of homozygous FFI. Furthermore, this FFI patient presented with parkinsonism in both M129M and M129V (Table).

Generally, the initial symptom of FFI is insomnia. In our case, the initial symptom was parkinsonism, while another report on FFI described a unique case in which the initial symptom was dementia (11). Thus, the initial symptoms of FFI are considered to be heterogeneous. Our case emphasizes the possibility that isolated parkinsonism may occur as an initial symptom in FFI, instead of insomnia; however, this parkinsonism was refractory to levodopa therapy and progressed rapidly, which differentiated it from DLB or other diseases associated with parkinsonian symptoms.

The authors declare no conflicts of interest in association with the present study.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement
We would like to thank Prof. Tetsuyuki Kitamoto (Department of Neurological Science, Tohoku University) for the PRNP analysis and Prof. Katsuya Satoh (Department of Locomotive Rehabilitation Sciences, Nagasaki University Graduate School of Medicine) for the 14-3-3 protein detection.

References

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).